Purdel Carmen, Ungurianu Anca, Adam-Dima Ines, Margină Denisa
"Carol Davila" University of Medicine and Pharmacy, Faculty of Pharmacy, Department of Toxicology, Traian Vuia 6, Bucharest 020956, Romania.
"Carol Davila" University of Medicine and Pharmacy, Faculty of Pharmacy, Department of Biochemistry, Traian Vuia 6, Bucharest 020956, Romania.
Biomed Pharmacother. 2023 May;161:114468. doi: 10.1016/j.biopha.2023.114468. Epub 2023 Mar 1.
Probiotics are frequently consumed as functional food and widely used as dietary supplements, but are also recommended in treating or preventing various gastrointestinal diseases. Therefore, their co-administration with other drugs is sometimes unavoidable or even compulsory. Recent technological developments in the pharmaceutical industry permitted the development of novel drug-delivery systems for probiotics, allowing their addition to the therapy of severely ill patients. Literature data regarding the changes that probiotics could impose on the efficacy or safety of chronic medication is scarce. In this context, the present paper aims to review probiotics currently recommended by the international medical community, to evaluate the relationship between gut microbiota and various pathologies with high impact worldwide and, most importantly, to assess the literature reports concerning the ability of probiotics to influence the pharmacokinetics/pharmacodynamics of some widely used drugs, especially for those with narrow therapeutic indexes. A better understanding of the potential influence of probiotics on drug metabolism, efficacy and safety could contribute to improving therapy management, facilitating individualized therapy and updating treatment guidelines.
益生菌常作为功能性食品食用,并广泛用作膳食补充剂,但也被推荐用于治疗或预防各种胃肠道疾病。因此,它们有时不可避免甚至必须与其他药物联合使用。制药行业最近的技术发展使得开发新型益生菌药物递送系统成为可能,从而能够将其添加到重症患者的治疗中。关于益生菌可能对慢性药物疗效或安全性产生的变化的文献数据很少。在此背景下,本文旨在综述国际医学界目前推荐的益生菌,评估肠道微生物群与全球范围内具有重大影响的各种疾病之间的关系,最重要的是,评估有关益生菌影响某些广泛使用药物的药代动力学/药效学能力的文献报道,尤其是那些治疗指数较窄的药物。更好地了解益生菌对药物代谢、疗效和安全性的潜在影响,有助于改善治疗管理,促进个体化治疗并更新治疗指南。